Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ: AGEN )

1.751 +0.071 (+4.23%)
Streaming Delayed Price Updated: 11:02 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
From Agenus Inc.
Via Business Wire
Agenus to Participate in September Investor Conferences
From Agenus Inc.
Via Business Wire
Agenus (AGEN) Q2 2024 Earnings Call Transcript
AGEN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q2 2024
AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Agenus Reports Second Quarter 2024 Operational and Financial Results
From Agenus Inc.
Via Business Wire
Agenus Announces Appointment of Tom Harrison to Board of Directors
From Agenus Inc.
Via Business Wire
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
From Agenus Inc.
Via Business Wire
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy... 
Via Benzinga
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity
Agenus faces a setback as the FDA advises against accelerated approval for its immunotherapy combination, botensilimab and balstilimab, for relapsed/refractory microsatellite-stable colorectal cancer.... 
Via Benzinga
Exposures Product Safety
AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm
From Schall Law Firm
Via Business Wire
Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views
Via Benzinga
Topics Earnings
Exposures Financial
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Dow Dips 250 Points; US Weekly Jobless Claims Surge
Via Benzinga
Topics Stocks
Exposures US Equities
WBD Stock Pops as Warner Bros. Considers Streaming Spinoff
Warner Bros. stock is rising on Thursday as reports about a potential spinoff of its streaming division embolden WBD investors. 
Via InvestorPlace
Agenus Loses More Than 50% Value On Thursday - Here's Why
Agenus shares drop amid FDA's feedback on its immunotherapy combo botensilimab and balstilimab for colorectal cancer. The FDA advised against accelerated approval, citing concerns about survival... 
Via Benzinga
Exposures Product Safety
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
NKGen Biotech stock is up Thursday as NKGN holders react to plans for a presentation at the Alzheimer’s Association International Conference. 
Via InvestorPlace
Why Is Agenus (AGEN) Stock Down 55% Today?
Agenus stock is down on Thursday after the company provided AGEN investors with an update on a Phase 2 clinical trial meeting. 
Via InvestorPlace
US Stocks Edge Higher; D.R. Horton Posts Upbeat Earnings
Via Benzinga
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
From Agenus Inc.
Via Business Wire
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
From Agenus Inc.
Via Business Wire
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
From Agenus Inc.
Via Business Wire
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
From Agenus
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Agenus Announces Virtual Annual Shareholders Meeting
From Agenus Inc.
Via Business Wire
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended. 
Via InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.